Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects With Social Anxiety Disorder (SAD)

NCT05030350 is registered in ClinicalTrials.gov with VistaGen Therapeutics, Inc. as lead sponsor.

NCT NCT05030350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05030350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects With Social Anxiety Disorder (SAD)
Lead sponsor
VistaGen Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
October 1, 2021
Completion date
September 23, 2022
Enrollment
481 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

social anxiety disorder